pancreatic cancer
Conditions
Interventions
Duration: 3 months Dose Neoadjuvant chemoradiation: Gemcitabine(150mg/m2/w)+RT(50.4G/28f) Metformin: from 5days before starting neoadjuvant chemoradiation until surgery.(1500mg/3x)
Sponsors
Hokkaido University Graduate School of Medicine Gastroenterological Surgery 1
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1) Certification of pancreatic cancer (histological confirmation is desired). 2) Beyond borderline resectable pancreatic cancer (NCCN guideline 2013 ver.1). 3) No prior anti-tumor therapy for pancreatic cancer. 4) Patient age: over 20 years old, 80 years old or less. 5) Performance status (ECOG) is 0 or 1. 6) Essential organ function is preserved. WBC counts: over 3000/mm3 Neutrophil counts: over 2000/mm3 Platelets counts: over10^4/mm3 Hb: over 9 g/dl TBil: below 3.0 mg/dl AST/ALT: 5 times less than the upper limit of normal Serum creatinine: below 1.3mg/dl (male) 1.2mg/dl (female) 7) Patients with type 2 diabetes 8) Written consent has been obtained from the patient himself.
Exclusion criteria
Exclusion criteria: 1) Pulmonary fibrosis or interstitial pneumonia 2) severe infectious disease 3) Patients with uncontrolled heart failure , angina, arrhythmias, and myocardial infarction within 6 months after the onset. 4) uncontrolled diabetes 5) Patients with active infection 6) Patients with pregnant women, the possibility or intention of lactating and pregnant. 7)severe drug allergy 8)peptic ulcer and bleeding 9)obvious neurological disorder or mental disorder 10)active double cancer 11)Patients who are already administered metformin 12)other severe complications 13)The patients who are judged inadequate to the present study by Principal investigator or researcher.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| the ratio of histological remnant cancer cells | — |
Countries
Japan
Contacts
Public ContactTatsuhiko Kakisaka
Hokkaido University Hospital Gastroenterological Surgery 1
Outcome results
None listed